Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a

Rania M El-Lababidi; Mohamad Mooty; Maria-Fernanda Bonilla; Nouran M Salem

doi:10.1016/j.idcr.2020.e00837

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a

IDCases. 2020 May 22:21:e00837. doi: 10.1016/j.idcr.2020.e00837. eCollection 2020.

Authors

Rania M El-Lababidi¹, Mohamad Mooty², Maria-Fernanda Bonilla³, Nouran M Salem⁴

Affiliations

¹ Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, p.o. box 112412, Abu Dhabi, United Arab Emirates.
² Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, p.o. box 112412, United Arab Emirates.
³ Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
⁴ Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

Abstract

The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.

Keywords: Coronavirus disease 2019; Interferons; Pegylated interferon alfa 2a; SARS-CoV-2.

Publication types

Case Reports